Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Zoledronic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Darunavir, Cobicistat; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: Etrumadenant, Itraconazole; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 231
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more

Conditions: Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions: LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more

Conditions: Nausea and Vomiting, Postoperative
Interventions: dexamethasone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 7 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: St. John's Wort; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir, Healthy Volunteers
Interventions: Isavuconazole, Lopinavir/ritonavir; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions: miroliverELAP treatment; Combination Product
Lead sponsor: Miromatrix Medical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more

Conditions: Healthy Volunteers
Interventions: Glasdegib, Rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: Tobacco Product Beliefs and Use
Interventions: Modified Risk Claim Type - None, Product Brand - General Snus, Product Brand - Copenhagen, Modified Risk Claim Type - Multiple Diseases, Modified Risk Claim Type - Lung Cancer; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 21 Years and older
Enrollment: 1,257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
Interventions: Cyanocobalamin, Dulaglutide; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions: Semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 88
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Internet co-management module; Behavioral
Lead sponsor: Robert Wood Johnson Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 7
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota • Omaha, Nebraska + 3 more

Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
Interventions: CYNK-001; Biological
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Denver, Colorado • Chicago, Illinois • Hackensack, New Jersey + 6 more

Conditions: Effects of Chemotherapy
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: BMS-986325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Gastroparesis
Interventions: GSK962040, Ketoconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Vaping, Nicotine Absorption
Interventions: E-cigarette, P4M3-1.7%, P4M3-1.7%LA, P4M3-3%LA, P4M3-4%LA; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: HIV Infections
Interventions: Leflunomide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

Determining the Effect on Patients of Internet-Based Diabetes Disease Management

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Assessing Urinary Hormones in Female Cancer Survivors

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

GSK962040 Drug-drug Interaction Study With Ketoconazole

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients